These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25667277)

  • 21. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
    Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
    Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
    [No Abstract]   [Full Text] [Related]  

  • 22. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
    Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564
    [No Abstract]   [Full Text] [Related]  

  • 23. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
    Riess JW; Padda SK; Bangs CD; Das M; Neal JW; Adrouny AR; Cherry A; Wakelee HA
    Clin Lung Cancer; 2013 Sep; 14(5):592-5. PubMed ID: 23810364
    [No Abstract]   [Full Text] [Related]  

  • 25. ROS1-targeted therapy in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
    [No Abstract]   [Full Text] [Related]  

  • 26. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Gerlinger M; Norton L; Swanton C
    N Engl J Med; 2013 Sep; 369(12):1172-3. PubMed ID: 24047073
    [No Abstract]   [Full Text] [Related]  

  • 27. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Guisier F; Piton N; Salaun M; Thiberville L
    Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
    [No Abstract]   [Full Text] [Related]  

  • 28. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Crizotinib Treatment Combined with Resection and Whole-brain Radiation Therapy 
in A ROS1 Rearranged Lung Adenocarcinoma with Brain Metastasis: 
Case Report and Literature Review].
    Zhang M; Nie L; Zhang J
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):525-9. PubMed ID: 27561802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ROS1 gene rearrangement is identified in NSCLC.
    Cancer Discov; 2012 Feb; 2(2):OF9. PubMed ID: 22585869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review.
    Liu L; Wu J; Zhao W; Huang MJ
    Medicine (Baltimore); 2017 May; 96(21):e6979. PubMed ID: 28538401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer.
    Viola P; Maurya M; Croud J; Gazdova J; Suleman N; Lim E; Newsom-Davis T; Plowman N; Rice A; Montero MA; Gonzalez de Castro D; Popat S; Nicholson AG
    J Thorac Oncol; 2016 Jul; 11(7):1029-39. PubMed ID: 27179848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
    J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
    [No Abstract]   [Full Text] [Related]  

  • 34. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
    Xu CW; Wang WX; Huang RF; He C; Liao XH; Zhu YC; Du KQ; Zhuang W; Chen YP; Chen G; Fang MY
    Thorac Cancer; 2017 Nov; 8(6):714-719. PubMed ID: 28845578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma.
    Jenkins TM; Morrissette JJD; Kucharczuk JC; Deshpande CG
    Int J Surg Pathol; 2018 Jun; 26(4):360-363. PubMed ID: 29295663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib.
    Ju L; Han M; Su J; Wu C; Dong Z
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):561-564. PubMed ID: 30083883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Komiya T; Thomas A; Khozin S; Rajan A; Wang Y; Giaccone G
    J Clin Oncol; 2012 Sep; 30(27):3425-6; author reply 3426. PubMed ID: 22891268
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
    Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
    Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.